

Prostaglandin I2 enhances cough reflex sensitivity to capsaicin in the asthmatic airway

著者	Ishiura Yoshihisa, Fujimura Masaki, Nobata Kouichi, Oribe Yoshitaka, Abo Miki, Myou Shigeharu
journal or publication title	Cough
volume	3
number	2
page range	1-7
year	2007-11-12
URL	http://hdl.handle.net/2297/7280

doi: 10.1186/1745-9974-3-2

Research

Open Access

Prostaglandin I₂ enhances cough reflex sensitivity to capsaicin in the asthmatic airway

Yoshihisa Ishiura*¹, Masaki Fujimura², Kouichi Nobata², Yoshitaka Oribe¹, Miki Abo¹ and Shigeharu Myou²

Address: ¹The Department of Internal Medicine, Toyama City Hospital, Toyama, Japan and ²Respiratory Medicine, Cellular Transplantation Biology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan

Email: Yoshihisa Ishiura* - ishiura-@p2322.nsk.ne.jp; Masaki Fujimura - fujimura@med3.m.kanazawa-u.ac.jp; Kouichi Nobata - k-nobata@yg7.so-net.ne.jp; Yoshitaka Oribe - oribe@med3.m.kanazawa-u.ac.jp; Miki Abo - abo@med3.m.kanazawa-u.ac.jp; Shigeharu Myou - myous@nifty.com

* Corresponding author

Published: 12 January 2007

Received: 16 November 2005

Cough 2007, 3:2 doi:10.1186/1745-9974-3-2

Accepted: 12 January 2007

This article is available from: <http://www.coughjournal.com/content/3/1/2>

© 2007 Ishiura et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Inflammatory mediators are involved in the pathogenesis of airway inflammation, but the role of prostaglandin I₂ (PGI₂) remains obscure. This study was designed to investigate the role of PGI₂ in cough reflex sensitivity of the asthmatic airway, which is characterized by chronic eosinophilic airway inflammation. The effect of beraprost, a chemically and biologically stable analogue of PGI₂, on cough response to inhaled capsaicin was examined in 21 patients with stable asthma in a randomized, placebo-controlled cross over study. Capsaicin cough threshold, defined as the lowest concentration of capsaicin eliciting five or more coughs, was measured as an index of airway cough reflex sensitivity. The cough threshold was significantly ($p < 0.05$) decreased after two weeks of treatment with beraprost [17.8 (GSEM 1.20) μ M] compared with placebo [30.3 (GSEM 1.21) μ M]. PGI₂ increases cough reflex sensitivity of the asthmatic airway, suggesting that inhibition of PGI₂ may be a novel therapeutic option for patients with asthma, especially cough predominant asthma.

Background

Chronic cough is one of the commonest respiratory symptoms. Cough has been considered to be a defense mechanism of the airway to remove irritant particles or excess mucus, whereas non-productive cough, which is not associated with the clearance of the tracheobronchial mucus, may occur via increased cough reflex sensitivity. Inflammatory mediators such as prostaglandins may adjust the cough reflex sensitivity. However, little is known about how cough reflex sensitivity is influenced by airway inflammatory processes. Although our previous study has clearly shown that arachidonate cyclooxygenase products can modulate airway cough reflex sensitivity to inhaled

capsaicin [1], the effects of other mediators remains unknown.

It has been recognized that prostaglandin I₂ (PGI₂, prostacyclin) is the most abundant prostanoid generated on IgE-dependent challenge of human lung tissue in vitro [2,3]. Others reported that alveolar macrophages are able to synthesize large amount of PGI₂ [4]. These findings indicate that PGI₂ may play some role in the asthmatic airway and can affect airway cough reflex sensitivity. This study was conducted to elucidate this hypothesis. We investigated the effect of oral administration of beraprost, a chemically and biologically stable analog of PGI₂

{sodium (\pm)-4[(1R, 2R, 3aS, 8bS)-1, 2, 3a, 8b-tetrahydro-2-hydroxyl 2[(3S, 4RS)-3-hydroxy-4-methyl-oct-6-yne-(E)-1-enyl]-5-cyclopenta [b] benzofuranyl] butyrate}, on cough reflex sensitivity to inhaled capsaicin in patients with stable asthma [5].

Subjects and Methods

Subjects

Twenty-one patients with bronchial asthma (12 males and 9 females) with a mean age of 73.2 ± 1.5 (\pm SEM) (range 54–83) yrs participated in this study. All patients were lifetime nonsmokers or ex-smokers with no history of viral infection for at least 4 weeks prior to the study. Characteristics of individual patients are shown in Table 1. Informed consent was obtained from all subjects. This study was approved by the Ethics Committee of our hospital.

Each asthmatic patient satisfied the American Thoracic Society definition of asthma, with symptoms of episodic wheezing, cough, and shortness of breath responding to bronchodilators, and reversible airflow obstruction documented on at least one previous pulmonary function

study [6]. Reversibility was defined as greater than 12 % and 200 ml increase in the forced expiratory volume in one second (FEV1) following a bronchodilator inhalation (Table 1). All patients had bronchial hyperresponsiveness as shown in Table 1. Classification of asthma severity was defined according to Global Strategy for Asthma Management and Prevention. Patients with atopy were recognized as having a hereditary tendency to produce IgE antibodies against common environmental allergens [7]. This study was carried out when symptoms were mild and stable, while patients were taking oral theophylline, oral (short-acting clenbuterol) and/or aerosol β_2 -agonists (short-acting procaterol), inhaled steroids (beclomethasone dipropionate), inhaled anti-cholinergic agents (oxitropium bromide) and/or mucolytic agents (carbocysteine) according to previous reports [8-10]. They had not received oral steroids for at least eight weeks.

Assessment of cough reflex sensitivity to inhaled capsaicin

Cough reflex sensitivity was assessed by capsaicin provocation test [11]. Capsaicin (30.5 mg) was dissolved in Tween 80 (1 mL) and ethanol (1 mL) and then dissolved in physiological saline (8 mL) to make a stock solution of

Table 1: Clinical characteristics of patients

Patient number	Age (yr)	Sex	Height (cm)	Type	Severity	Total IgE in serum (IU/ml)	Specific IgE in serum	Complication of allergic disease	PC20-FEV1 (mg/ml)*	Bronchodilator response (%)**	Treatment			
											BDP (μ g/day)	Theophylline (mg/day)	Clenbuterol (μ g/day)	Carbocysteine (mg/day)
1	54	M	161	Int	Moderate	420	-	-	2.5	15.2	800	400	40	0
2	72	F	147	Ext	Moderate	642	Mite, HD	AR	0.31	31.5	800	400	0	0
3	70	M	161	Ext	Mild	312	Mite, HD, Cedar	-	0.08	20.2	0	600	0	0
4	71	F	140	Int	Mild	17	-	-	1.25	17.6	800	0	0	0
5	83	M	154	Ext	Moderate	345	Mite, HD, Cedar	-	5	17.1	800	400	40	1500
6	71	M	165	Ext	Moderate	146	Mite, HD	AR	1.25	15.6	0	0	40	0
7	77	F	144	Int	Mild	51	-	-	0.31	17.9	0	0	0	1500
8	71	M	155	Int	Mild	42	-	-	2.5	29.4	800	0	0	1500
9	80	M	152	Int	Moderate	66	-	-	1.25	39	800	0	0	0
10	75	M	162	Ext	Mild	143	Candida	-	2.5	14.1	800	0	0	0
11	80	F	145	Ext	Mild	3	HD, Cedar	-	0.08	37.1	800	0	0	0
12	63	F	154	Ext	Moderate	77	Cedar	AR	1.25	14.7	800	0	0	0
13	77	F	142	Int	Mild	105	-	-	5	17	0	400	20	0
14	70	M	155	Int	Moderate	82	-	-	0.31	15.4	800	0	0	1500
15	70	F	151	Ext	Mild	467	Mite, HD	-	2.5	20.4	800	400	40	0
16	72	F	150	Int	Mild	57	-	-	5	22.3	600	0	0	1500
17	81	M	163	Int	Moderate	64	-	-	0.31	33.4	800	600	40	1500
18	71	M	150	Int	Moderate	107	-	-	5	16.4	800	400	40	0
19	80	M	160	Int	Mild	87	-	-	2.5	29.5	0	400	0	0
20	68	M	167	Ext	Mild	264	Cedar	-	5	27	0	400	40	0
21	80	F	152	Int	Mild	54	-	-	2.5	17.3	0	400	0	0

Ext, extrinsic; Int. Intrinsic; HD, house dust; AR, allergic rhinitis; UR, urticaria; BDP, beclomethasone dipropionate inhalation.

* PC20-FEV1 shows concentration of inhaled methacholine causing a 20% fall in FEV1.

** Bronchodilator response means percent increase in forced expiratory volume in 1s (FEV1) from the baseline value after inhalation of 300 μ g of salbutamol sulfate.

All patients used inhaled β_2 -agonists (salbutamol or procaterol) on demand.

1×10^{-2} M, which was stored at -20°C . This solution was diluted with physiological saline to make solutions starting at a concentration of $0.49 \mu\text{M}$ and increasing it by doubling concentrations up to $1000 \mu\text{M}$. Each subject inhaled a control solution of physiological saline followed by progressively increasing concentrations of the capsaicin solution. Solutions were inhaled for 15 s every 60 s, by tidal mouth-breathing wearing a noseclip from a Bennett Twin nebulizer (3012-60 cc, Puritan-Bennett Co., Carlsbad, California, USA). Increasing concentrations were inhaled until five or more coughs were elicited. The nebulizer output was 0.21 mL/min. The number of capsaicin-induced coughs was counted by a blinded medical technician in our pulmonary function laboratory. The cough threshold was defined as the lowest concentration of capsaicin that elicited five or more coughs.

Study protocol (Figure 1)

The medication was stopped at 9.00 p.m. on the previous day to allow a washout time of 12 h or more before the measurement of cough threshold to inhaled capsaicin at 10.00 a.m. on each test day to reduce the diurnal variability of the cough response.

Each patient attended 4 times separated by 2 weeks, at the same time each day. Control measurement of capsaicin cough threshold was carried out 2 weeks before initiation of the first treatment (run-in). Two weeks treatment with beraprost sodium or placebo was performed separated by


a two-week washout period in a randomized, cross-over fashion. Two beraprost sodium tablets ($40 \mu\text{g}$) and their placebo were taken orally three times a day for 14 days and at 8.00 a.m. on the test day. FEV1 was measured on a dry wedge spirometer (Transfer Test, P.K. Morgan Ltd., UK) before capsaicin challenge to assess the bronchoactive effect of the treatment regimens. Serum total IgE levels and the number of peripheral eosinophils were measured to assess anti-allergic effect of the test drugs.

Data analysis

Capsaicin cough threshold values were expressed as geometric mean with geometric standard error of the mean (GSEM). Forced vital capacity (FVC), FEV1 and maximal mid expiratory flow (MMF) were shown as arithmetic mean values \pm SEM. The FVC values, the FEV1 values and the MMF values were compared between each pair of the four groups (run-in, washout, beraprost sodium and placebo) by the Wilcoxon signed-ranks test. A p-value of 0.05 or less was taken as significant.

Results

Cough threshold to inhaled capsaicin before each treatment (run-in, washout) and after treatment with beraprost and placebo are shown in Figure 2. Geometric mean values for the cough threshold were 29.5 (GSEM 1.17) μM in the run-in period, 26.5 (GSEM 1.18) μM in the washout period, 17.8 (GSEM 1.20) μM after beraprost treatment and 30.3 (GSEM 1.21) μM after placebo treatment.



* Treatment with beraprost 120 mg/day or placebo in a randomized, cross-over fashion

Increasing concentrations of capsaicin were inhaled for 15s every 60s, until five or more coughs were counted.

Concentrations of capsaicin solution were

0.49, 0.98, 1.95, 3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500 and 1000 μM

Figure 1
Study protocol.

The cough threshold after the beraprost treatment was significantly ($p < 0.05$) lower than the value after the placebo treatment. FVC, FEV₁ or MMF value was not significantly different between run-in period, washout period, beraprost treatment and placebo treatment as shown in Table 2.

Figure 3 and figure 4 show the changes in serum IgE and peripheral blood eosinophils, respectively. Treatment with beraprost did not affect the IgE production or peripheral blood eosinophil count.

Discussion

The present study showed that two-week treatment with a stable PGI₂ analogue, beraprost, decreased the cough threshold to inhaled capsaicin in asthmatic patients. No difference could be found in the baseline pulmonary function, IgE production or peripheral eosinophil count between beraprost and placebo treatments. These findings suggest that PGI₂ enhances the cough reflex sensitivity in the asthmatic airway.

Cough is one of the main symptoms of bronchial asthma which can profoundly and adversely affect the quality of patient's lives and social activities, whereas the mechanisms underlying the cough remain obscure. Previous researchers [12] indicated that cough receptors are stimulated by local bronchoconstriction. This finding may be one of the causes of cough in bronchial asthma. However, recent studies about cough variant asthma (CVA) revealed normal baseline pulmonary function and mild bronchial hyperresponsiveness [13,14]. Our previous study has also demonstrated that inhaled procaterol in a dose sufficient to produce bronchodilation has no effect on airway cough receptor sensitivity in asthma [15]. O'Connell and colleagues have reported that cough reflex sensitivity is increased in some asthmatic patients suffering from daily coughing and recovers to normal range after relief of the cough on treatment [16]. These findings suggest that cough reflex hypersensitivity is another mechanism of chronic non-productive cough in asthma, in addition to cough receptor stimulation by local bronchoconstriction [12].

It has been revealed that inflammatory mediators such as arachidonate metabolites play major roles in the pathogenesis of bronchial asthma, however, the relationship

between inflammatory mediators and airway cough reflex sensitivity remains obscure. Some studies indicated that some inflammatory mediators might modulate the sensitivity of cough reflex [1,17]. We showed that intrinsic thromboxane A₂ (TxA₂) is a possible modulator augmenting both airway cough reflex sensitivity and bronchial responsiveness while it does not have bronchoconstricting effect in stable asthmatics [1,18,19]. Other researchers reported that prostaglandin F_{2α} (PGF_{2α}) enhances airway cough reflex sensitivity with bronchoconstricting effect [2,20]. It has been also shown that inhaled prostaglandin E₂ (PGE₂), which acts as a bronchodilator, enhances cough reflex sensitivity [20,21]. Although cysteinyl leukotrienes (cLTs) play an important role in bronchomotor tone of the asthmatic airway, their role in cough reflex sensitivity is controversial [19,22]. These findings indicate that arachidonate metabolites including prostaglandins may have variable roles in the local control of the cough reflex with no relation to bronchoconstriction.

It has been known that PGI₂ is the most abundant prostanoid generated on IgE-dependent challenge of human lung tissue in vitro [2,3]. Others reported that alveolar macrophages are able to synthesize a large amount of PGI₂ [4]. These findings imply that PGI₂ plays some role in asthmatic airway. Although PGI₂ causes relaxation of isolated precontracted human bronchus [23], its clinical effect is limited: short-term protection against immediate bronchoconstriction provoked by exercise [24], and nebulized distilled water [24] but not by allergen [25] or aspirin [26]. Therefore, the exact role of PGI₂ in asthmatic airway remains obscure. Hardy et al. reported an irritative effect of single inhalation of PGI₂ on human airways [27], but influence of repeated administration has not been studied. Szczeklik and their colleagues also reported that four out of twelve asthmatic patients complained of coughing during PGI₂ inhalation [28]. However, these previous reports have not investigated the change of cough reflex sensitivity. Thus the exact role of PGI₂ in airway cough reflex sensitivity also remains unknown. We observed that some patients complained of coughing on treatment with beraprost but none did with placebo. The implication of this study is that PGI₂ may be involved in the pathogenesis of cough reflex sensitivity rather than

Table 2: Pulmonary function on beraprost and placebo treatments in patients with bronchial asthma

	Run-in	Placebo	Washout	Beraprost
FVC as % pred. (%)	96.8 ± 5.7	103.4 ± 3.3	104.4 ± 3.1	103.4 ± 3.4
FEV ₁ as% pred. (%)	90.9 ± 5.7	94.1 ± 5.5	93.0 ± 5.6	93.2 ± 5.6
MMF as% pred. (%)	50.7 ± 6.7	52.0 ± 6.0	50.1 ± 6.4	51.5 ± 6.4

Data are shown as standard error of the mean for FVC, FEV₁ and MMF.

* $p < 0.05$ compared with each control value (Wilcoxon signed-ranks test).




Figure 2

Individual data of capsaicin cough threshold at run-in period, at washout period and on treatment with beraprost and placebo in patients with stable bronchial asthma. Each horizontal bar represents geometric mean value. Closed circles and open circles represent patients undergoing steroid inhalation therapy and patients without steroid inhalation therapy, respectively. P values: Wilcoxon signed-ranks test using logarithmically transformed values.




Figure 3

Individual data of serum IgE at run-in period, at washout period and on treatment with beraprost and placebo in patients with stable bronchial asthma. Each horizontal bar represents geometric mean value. Closed circles and open circles represent patients undergoing steroid inhalation therapy and patients without steroid inhalation therapy, respectively. P values: Wilcoxon signed-ranks test using logarithmically transformed values.




Figure 4

Individual data of peripheral blood eosinophils at run-in period, at washout period and on treatment with beraprost and placebo in patients with stable bronchial asthma. Each horizontal bar represents geometric mean value. P values: Wilcoxon signed-ranks test.

bronchodilation and it may explain the role of PGI₂ in the asthmatic airway which has been unknown so far.

Overall, our data support the conclusion that inhibition of PGI₂ formation or action may be a novel treatment for chronic non-productive cough in asthmatic airway, especially in cough variant asthma or cough predominant asthma with normal baseline pulmonary function. This is the first report demonstrating the role of PGI₂ in cough reflex sensitivity in the asthmatic airway. Further studies may be required to elucidate the role of PGI₂ in other eosinophilic bronchial disorders presenting with non-productive cough with normal baseline pulmonary functions [29-31].

Abbreviations

cLT = cysteinyl leukotriene; CVA = cough variant asthma; FEV₁ = forced expiratory volume in one second; FVC = forced vital capacity; GSEM = geometric standard error of the mean; PGE₂ = prostaglandin E₂; PGF₂α = prostaglandin F₂α; PGI₂ = prostaglandin I₂; MMF = maximal mid expiratory flow; TxA₂ = thromboxane A₂.

Acknowledgements

This study was supported in part by a grant-in-aid for Scientific Research from the Ministry of Education, Science and Culture (17607003) by the Japanese Government.

References

1. Fujimura M, Kamio Y, Kasahara K, Bando T, Hashimoto T, Matsuda T: **Prostanoids and cough response to capsaicin in asthma and chronic bronchitis.** *Eur Respir J* 1995, **8**:1499-1505.
2. Horton EW: **Prostaglandins and smooth muscle.** *Br Med Bull* 1979, **35**:295-300.

3. Schulman ES, Adkinson NF, Newball HH: **Cyclooxygenase metabolites in human lung anaphylaxis. Airways vs. parenchyma.** *J Appl Physiol* 1982, **53**:589-595.
4. Hsueh W, Kuhn GIII, Needleman P: **Relationship of prostaglandin secretion by rabbit alveolar macrophages to phagocytosis and lysosomal enzyme release.** *Biochem J* 1979, **184**:345-54.
5. Akiba T, Miyazaki M, Toda N: **Vasodilator actions of TKR-100, a new prostaglandin I₂ analogue.** *Br J Pharmacol* 1986, **89**:703-711.
6. American Thoracic Society: **Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma.** *Am Rev Respir Dis* 1987, **136**:225-244.
7. Kay AB: **Allergy and allergic diseases.** *N Engl J Med* 2001, **344**:30-37.
8. Fujimura M, Kamio Y, Hashimoto T, Matsuda T: **Cough receptor sensitivity and bronchial responsiveness in patients with only chronic nonproductive cough: in view of effect of bronchodilator therapy.** *J Asthma* 1994, **31**:463-72.
9. Boner AL, Vallone G, Brighenti C, Schiassi M, Miglioranza P, Richelli C: **Comparison of the protective effect and duration of action of orally administered clenbuterol and salbutamol on exercise-induced asthma in children.** *Pediatr Pulmonol* 1988, **4**:197-200.
10. Ishiura Y, Fujimura M, Yamamori C, Nobata K, Myou S, Kurashima K, Michishita Y, Takegoshi T: **Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients.** *Br J Clin Pharmacol* 2003, **55**:504-10.
11. Fujimura M, Sakamoto S, Kamio Y, Matsuda T: **Effects of methacholine-induced bronchoconstriction and procaterol-induced bronchodilation on cough receptor sensitivity to inhaled capsaicin and tartaric acid.** *Thorax* 1992, **47**:441-45.
12. Salem H, Aviado DM: **Antitussive drugs.** *Am J Med Sci* 1964, **247**:585-600.
13. Corrao WM, Braman SS, Irwin RS: **Chronic cough as the sole presenting manifestation of bronchial asthma.** *N Engl J Med* 1979, **300**:633-637.
14. Koh YY, Chae SA, Min KU: **Cough variant asthma is associated with a higher wheezing threshold than classic asthma.** *Clin Exp Allergy* 1993, **23**:696-701.
15. Fujimura M, Sakamoto S, Kamio Y, Bando T, Kurashima K, Matsuda T: **Effect of inhaled procaterol on cough receptor sensitivity in patients with asthma or chronic bronchitis and in normal subjects.** *Thorax* 1993, **48**:615-618.

16. O'Connell F, Thomas VE, Pride NB, Fuller RW: **Capsaicin cough sensitivity decreases with successful treatment of chronic cough.** *Am J Respir Crit Care Med* 1994, **150**:374-380.
17. Choudry NB, Fuller RW, Pride NB: **Sensitivity of the human cough reflex: Effect of inflammatory mediators prostaglandin E2, bradykinin, and histamine.** *Am Rev Respir Dis* 1989, **140**:137-141.
18. Fujimura M, Sakamoto S, Saito M, Miyake Y, Matsuda T: **Effect of a thromboxane A2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in asthmatic subjects.** *J Allergy Clin Immunol* 1991, **87**:23-27.
19. Fujimura M, Kamio Y, Hashimoto T, Matsuda T: **Thromboxane A2 and sulfidopeptide leukotrienes in cough reflex in response to inhaled capsaicin in asthmatic subjects.** *J Jpn Soc Bronchology* 1998, **20**:4-10.
20. Stones R, Barnes PJ, Fuller RW: **Contrasting effects of prostaglandins E2 and F2 on sensitivity of the human cough reflex.** *J Appl Physiol* 1992, **73**:649-653.
21. Wasserman MA, Griffin RL, Marsalisi FB: **Inhibition of bronchoconstriction by aerosols of prostaglandins E1 and E2.** *J Pharmacol Exp Ther* 1980, **214**:68-73.
22. Dicipinigitis PV, Dobkin JB: **Effect of zafirlukast on cough reflex sensitivity in asthmatics.** *J Asthma* 1999, **36**:265-70.
23. Gardiner PJ, Collier HO: **Specific receptors for prostaglandins in airways.** *Prostaglandins* 1980, **19**:819-841.
24. Bianco S, Robuschi M, Ceserani R, Gandolfi C, Kambuff P: **Prevention of specifically induced bronchoconstriction by PGI2 and 20-methyl-PGI2 in asthmatic patients.** *Pharmacol Res Commun* 1978, **10**:657-675.
25. Bianco S, Robuschi M, Ceserani R, Gandolfi C: **Effects of prostacyclin on aspecifically and specifically induced bronchoconstriction in asthmatic subjects.** *Eur J Respir Dis* 1980, **S106**:18-87.
26. Nizankowska E, Czerniawska-mysik, Szczeklik A: **Lack of effect of i.v. prostacyclin on aspirin induced asthma.** *Eur J Respir Dis* 1986, **69**:363-368.
27. Hardy C, Robinson C, Lewis RA, Tattersfield AE, Holgate ST: **Airway and cardiovascular responses to inhaled prostacyclin in normal and asthmatic subjects.** *Am Rev Respir Dis* 1985, **131**:18-21.
28. Szczeklik A, Gryglewski RJ, Nizankowska E, Nizankowski R, Musial J: **Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man.** *Prostaglandins* 1978, **16**:651-60.
29. Gibson PG, Dolovich J, Denburg J, Ramsdale EH, Hargreave FE: **Chronic cough: eosinophilic bronchitis without asthma.** *Lancet* 1989, **1(8651)**:1346-1348.
30. Fujimura M, Ogawa H, Yasui M, Matsuda T: **Eosinophilic tracheo-bronchitis and airway cough hypersensitivity in chronic non-productive cough.** *Clin Exp Allergy* 2000, **30**:41-47.
31. Brightling CE, Ward R, Goh KL, Wardlaw AJ, Pavord ID: **Eosinophilic bronchitis is an important cause of chronic cough.** *Am J Respir Crit Care Med* 1999, **160**:406-410.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:

http://www.biomedcentral.com/info/publishing_adv.asp

